Benzodiazepine formulation in a polyorthoester carrier
First Claim
1. An implantable drug depot useful for reducing or treating pain in a patient in need of such treatment, the drug depot comprising a polyorthoester in an amount of about 95 to 99 wt % based on the total weight of the drug depot, and mPEG, the drug depot comprising a gel and having a viscosity of about 500 to 10,000 centipoises and a benzodiazepine in an amount of about 1 to 5 wt. % based on the total weight of the drug depot and having a particle size of between about 5 μ
- m to 50 μ
m the drug depot adapted to be administered intraspinally in the patient to reduce or treat pain, wherein the drug depot is capable of releasing benzodiazepine for a period of at least 30 days after administration.
3 Assignments
0 Petitions
Accused Products
Abstract
Effective treatments of pain for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of a benzodiazepine, such as midazolam, formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days or at least one hundred and thirty-five days.
-
Citations
18 Claims
-
1. An implantable drug depot useful for reducing or treating pain in a patient in need of such treatment, the drug depot comprising a polyorthoester in an amount of about 95 to 99 wt % based on the total weight of the drug depot, and mPEG, the drug depot comprising a gel and having a viscosity of about 500 to 10,000 centipoises and a benzodiazepine in an amount of about 1 to 5 wt. % based on the total weight of the drug depot and having a particle size of between about 5 μ
- m to 50 μ
m the drug depot adapted to be administered intraspinally in the patient to reduce or treat pain, wherein the drug depot is capable of releasing benzodiazepine for a period of at least 30 days after administration. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
- m to 50 μ
Specification